{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:30:26Z","timestamp":1769556626019,"version":"3.49.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>There are limited bladder-preserving therapeutic options for patients with high-risk non-muscle invasive bladder cancer (NMIBC) after failed Bacillus Calmette-Gu\u00e9rin (BCG) therapy. Salvage intravesical docetaxel therapy was described in 2006 but has not been validated outside of the original institution. In this study, we presented the first external report on the oncologic outcomes of intravesical docetaxel.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods:<\/jats:title>\n            <jats:p>We identified 13 patients with high-risk NMIBC treated with \u22651 course of intravesical BCG who received salvage intravesical docetaxel. Recurrence-free survival (RFS) was estimated using the Kaplan\u2013Meier method. Associations of clinicopathologic features with RFS were evaluated using Cox regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Median age was 75.2\u200ayears, and 46.2% of patients were male. Of the patients 92.3% had a prior diagnosis of high-grade T1 disease, 38.5% had a prior diagnosis of carcinoma in situ, and 46.2% had received \u22652 courses of BCG. Only 1 (7.7%) patient experienced docetaxel-related toxicity. Nine (69.2%) patients had a complete response at initial post-docetaxel cystoscopy. During a median follow-up of 12.0 (interquartile range 5.0\u201318.1) months, a total of 7 (53.8%) patients developed recurrence. Median time to recurrence was 10.1 (interquartile range 4.8\u201311.6) months. Estimated RFS at 6-, 12-, 18-, and 24-months was 75%, 50%, 50%, and 25%. Three (23.1%) patients ultimately underwent cystectomy. On univariable analysis, multiple courses of induction BCG were associated with decreased RFS, although this did not reach statistical significance (hazard ratio 4.69, <jats:italic toggle=\"yes\">p<\/jats:italic>\u200a=\u200a0.08).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In this first external validation study, intravesical docetaxel was associated with excellent response rates and intermediate-term RFS among patients with high-risk NMIBC after failed BCG therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cu9.0000000000000010","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T12:01:17Z","timestamp":1617278477000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Gu\u00e9rin failure"],"prefix":"10.1097","volume":"15","author":[{"given":"Govind","family":"Shantharam","sequence":"first","affiliation":[{"name":"Warren Alpert School of Medicine of Brown University, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Amin","sequence":"additional","affiliation":[{"name":"Warren Alpert School of Medicine of Brown University, Providence, RI, USA"},{"name":"Department of Pathology and Laboratory Medicine, The Miriam Hospital, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Pereira","sequence":"additional","affiliation":[{"name":"Warren Alpert School of Medicine of Brown University, Providence, RI, USA"},{"name":"Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI, USA"},{"name":"Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohad","family":"Kott","sequence":"additional","affiliation":[{"name":"Warren Alpert School of Medicine of Brown University, Providence, RI, USA"},{"name":"Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI, USA"},{"name":"Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catrina","family":"Mueller-Leonhard","sequence":"additional","affiliation":[{"name":"Lifespan Oncology Clinical Research, The Miriam Hospital, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Mega","sequence":"additional","affiliation":[{"name":"Warren Alpert School of Medicine of Brown University, Providence, RI, USA"},{"name":"Department of Hematology\/Oncology, The Miriam Hospital, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragan","family":"Golijanin","sequence":"additional","affiliation":[{"name":"Warren Alpert School of Medicine of Brown University, Providence, RI, USA"},{"name":"Minimally Invasive Urology Institute, The Miriam Hospital, Providence, RI, USA"},{"name":"Division of Urology, Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Gershman","sequence":"additional","affiliation":[{"name":"Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"(3)","key":"R1-20250821","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"(4)","key":"R2-20250821","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"(10)","key":"R3-20250821","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.6004\/jnccn.2016.0131","article-title":"NCCN guidelines insights: bladder cancer, Version 2.2016","volume":"14","author":"Clark","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"(3)","key":"R4-20250821","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cncr.30392","article-title":"Non-muscle-invasive bladder cancer: intravesical treatments beyond Bacille Calmette-Guerin","volume":"123","author":"Packiam","year":"2017","journal-title":"Cancer"},{"issue":"(6)","key":"R5-20250821","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.urolonc.2015.12.004","article-title":"Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guerin","volume":"34","author":"Steinberg","year":"2016","journal-title":"Urol Oncol"},{"issue":"(3)","key":"R6-20250821","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"issue":"(4)","key":"R7-20250821","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review","volume":"109","author":"Shelley","year":"2012","journal-title":"BJU Int"},{"issue":"(3)","key":"R8-20250821","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"issue":"(30)","key":"R9-20250821","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for patients with high-grade, Bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"issue":"(4)","key":"R10-20250821","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"issue":"(1)","key":"R11-20250821","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"issue":"(8)","key":"R12-20250821","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1464-410X.2009.08543.x","article-title":"A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy","volume":"104","author":"Barlow","year":"2009","journal-title":"BJU Int"},{"issue":"(1)","key":"R13-20250821","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","article-title":"Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy","volume":"75","author":"Laudano","year":"2010","journal-title":"Urology"},{"issue":"(19)","key":"R14-20250821","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"(16)","key":"R15-20250821","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"R16-20250821","first-page":"CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"(5)","key":"R17-20250821","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"issue":"(3)","key":"R18-20250821","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"}],"container-title":["Current Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CU9.0000000000000010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:00:33Z","timestamp":1755795633000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CU9.0000000000000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cu9.0000000000000010","relation":{},"ISSN":["1661-7649","1661-7657"],"issn-type":[{"value":"1661-7649","type":"print"},{"value":"1661-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"2019-10-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}